N/A N=285 Get Connected Efficacy Trial
HIV Infections
Primary: Percent of Participants Reporting Changes in Their HIV Testing Behavior Using Self-report Questionnaires — 53; 54 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Tolerance to Residual Astigmatism in Eyes With Vivity®
Lenses, Intraocular
Primary: Distance Against the Rule Astimatism — 0.01 LogMAR
N/A N=52 Synergy Lens Outcomes Evaluation
Presbyopia · Pseudophakia
Primary: Binocular Distance Corrected Near Visual Acuity at 40 cm Under Photopic Conditions — 0.01 logMAR
N/A N=30 Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Social Responsiveness Scale (SRS) — 16.5; 89.06; 14.5; 79.8 Points
Phase 1 N=36 Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1579.19; 2204.35…
Phase 1 N=115 Effect of Dexlansoprazole on Bone Homeostasis
Homeostasis · Bone and Bones
Primary: Percent Change From Baseline to Week 26 in Bone Formation Marker Aminoterminal Propeptide of Type 1 Collagen (P1NP) — -0.4; 19.3; 16.9 percent change
Phase 3 N=149 Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
Meningococcal Vaccine
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2 — 19.7; 7.7; 0; 14.1 Percentage of participants
Phase 4 N=50 Safety of Argatroban Infusion in Conduction Disturbances
Stable Coronary Artery Disease (CAD) · Unstable Angina (Troponin Negative)
Primary: Mean Difference in QTc Interval Between ECG-2 and ECG-1 (ITT Population) — 0.94 milliseconds
Phase 1 N=48 A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
Healthy
Primary: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1227.91; 1150.18; 1718.47…
Phase 3 N=1,045 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
Respiratory Syncytial Virus Infections
Primary: Titers for Hemagglutination Inhibition (HI) Antibodies Against 4 FLU Vaccine Strains Expressed as Group Geometric Mean Titers (GMTs) at 1 Month After FLU Vaccine Dose…
N/A N=1,361 Performance Evaluation of the Lucira COVID-19 & Flu Test
COVID-19 · Influenza
Primary: Confirmation That the Lucira COVID-19 & Flu Test Provides Similar Performance to a High Complexity Lab Molecular Diagnostic RT-PCR Assay(s) With Known High Sensitivity…
N/A N=221 Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
Phase 4 N=64 Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
Beta Thalassemia Major Anemia · Iron Overload
Primary: The Percentage of Patients in Each Treatment Group Who Still Have a Serum Ferritin Level < 1000 Micrograms Per Liter (μg/L) at Month 12 — 21; 12 Participants — p=0.0446
N/A N=1,216 Pharmacy Delivery to Expand the Reach of PrEP in Kenya
HIV Prevention
Primary: PrEP Initiation — 287; 661 Participants
N/A N=30 Effects of Sleep Hygiene Education on Sleep Health in Community-Dwelling Older Adults
Sleep Habit, Good · Sleep Hygiene · Health Behavior
Primary: Change Score From Baseline to 4-week Follow up on the Pittsburgh Sleep Quality Index — 1.6; 2.5 units on a scale